The original proposal sought to tie price cuts to fluctuating healthcare revenues and national spending levels. Executives balked at the uncertainty, with Eli Lilly’s leadership threatening to halve a planned 2.3-billion-euro investment in the country. By moving to a fixed structure, Berlin aims to provide the predictability required for long-term manufacturing commitments.
Germany Scraps Variable Drug Discount Plan After Industry Backlash
Facing fierce resistance from pharmaceutical giants, the German government is abandoning its proposal to introduce variable drug discounts. Officials are now pivoting to a fixed-discount model, hoping to stabilize the industry’s investment climate while still addressing a massive 20-billion-euro shortfall in the national healthcare system.
The federal health ministry remains cautious, stating that no final decisions have been reached regarding the legislative overhaul. While the VFA industry association welcomed the shift in tone, they continue to press for a rigorous impact assessment before any new fiscal measures are locked into law. The government’s broader goal remains closing a 20-billion-euro funding gap to avoid raising mandatory health insurance premiums.
Comments (0)
No comments yet. Be the first!